May 18, 2015— AUA, New Orleans. A study of medical records of nearly 10,000 patients with prostate cancer shows that active surveillance (the updated form of watchful waiting) is suitable for most men with low-risk disease. Twelve to 15 years after diagnosis, these men are no more likely to die of prostate cancer than of other conditions and diseases. By contrast, the study shows, to avoid dying of prostate cancer men with high-risk disease may require aggressive "multimodal treatment" including surgery. ...continue reading Active Surveillance For Low-Risk Prostate Cancer Does Not Shorten Life
Category: Treatment News
Gene Subgroup C-MYC in Aggressive Gleason 7 Prostate Cancer
May help determine specialized treatment
PSA Rising via TORONTO, Canada – May 27, 2015 – Prostate cancer researchers in Canada have drawn a molecular portrait that provides the first complete picture of localized, multi-focal disease within the prostate and also unveils a new gene subgroup driving it.
...continue reading Gene Subgroup C-MYC in Aggressive Gleason 7 Prostate Cancer
Abiraterone rejection in Scotland must be overturned, Prostate Cancer advocate says
Advocating for advanced prostate cancer patients in Scotland, Alister Walker, Chairman and volunteer in Perth & Kinross Prostate Cancer Support Group, writes in the Scottish newspaper The Herald:
"Last week we read the good news that Moderator-Designate of the General Assembly of the Church of Scotland, the Reverend Dr Angus Morrison, has overcome the disease (Church leader in cancer warning , The Herald, April 23). With prostate cancer so often being symptomless in its early stages he is right to urge other men to consider speaking to their GP about the disease. This is particularly important for men aged over 50, black men and men whose father or brother has had the disease - who are at a higher risk. ...continue reading Abiraterone rejection in Scotland must be overturned, Prostate Cancer advocate says
Brachytherapy combination improves PSA-free survival for patients with higher-risk localized prostate cancer, trial finds
Men receiving the radioactive "seeds" were more likely to be cancer-free five to nine years later. ...continue reading Brachytherapy combination improves PSA-free survival for patients with higher-risk localized prostate cancer, trial finds
Injectable Gel Improves Radiation for Prostate Cancer
A device to lower side effects of radiation treatment for prostate cancer, newly approved in the USA, has been used this month on the first patient. The device injects a temporary gel to create a space between the prostate and the rectum.
Named the SpaceOAR System (“OAR” stands for “organ at risk”), the system received FDA clearance on April 1. FDA granted clearance after a US clinical trial showing that SpaceOAR hydrogel achieved a significant reduction in rectal radiation dose and late rectal toxicity.
...continue reading Injectable Gel Improves Radiation for Prostate Cancer
Cesium-131 Brachytherapy for Prostate Cancer Has Fewer Side Effects
January 7, 2006. A new radiation therapy for prostate cancer -- Cesium-131 brachytherapy -- has fewer side effects than other treatments. NewYork-Presbyterian Hospital/Weill Cornell Medical Center is the only hospital in the Northeast to offer the new therapy.
...continue reading Cesium-131 Brachytherapy for Prostate Cancer Has Fewer Side Effects